A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Subjects With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor
Latest Information Update: 31 Jul 2024
Price :
$35 *
At a glance
- Drugs Abiprubart (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use
- Sponsors Kiniksa Pharmaceuticals
- 15 Jun 2024 Results evaluating the safety and PK of multiple SC doses of abiprubart , presented at the 25th Annual Congress of the European League Against Rheumatism
- 14 Jun 2024 This trial has been completed in Bulgarian, according to the European Clinical Trials Database record.
- 06 Jun 2024 Status changed from active, no longer recruiting to completed.